Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial
Abstract Alzheimer’s disease (AD) is characterized by progressive cognitive decline, severe brain atrophy and neuroinflammation. We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial that tested the safety and efficacy of laromestrocel, a bone-marrow-der...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2025
|
| 在線閱讀: | https://doi.org/10.1038/s41591-025-03559-0 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|